Mineralys Therapeutics Files NDA for Lorundrostat, Anticipates Q1 Phase 2 OSA Data
Summary
Mineralys Therapeutics announced the submission of a New Drug Application (NDA) for its lead candidate, lorundrostat, to the U.S. FDA in late 2025, a critical step towards potential market approval. The company also confirmed it is on track to release topline results from its Phase 2 Explore-OSA trial in the first quarter of 2026.
Key Events
-
NDA Filed for Lorundrostat
Mineralys Therapeutics submitted a New Drug Application (NDA) to the U.S. FDA in late 2025 for lorundrostat, its lead drug candidate for hypertension and related comorbidities, following a successful clinical program.
-
Phase 2 Explore-OSA Results Expected
The company confirmed it is on track to report topline results from its Phase 2 Explore-OSA trial in the first quarter of 2026, evaluating lorundrostat for obstructive sleep apnea and hypertension.
Analysis
This 8-K filing signals a major advancement for Mineralys Therapeutics as it moves its lead drug candidate, lorundrostat, closer to potential commercialization. The NDA submission to the FDA in late 2025, following a successful clinical program, is a significant de-risking event for the company's primary asset. Lorundrostat is being developed for hypertension and related comorbidities, a large market. Additionally, the upcoming Phase 2 Explore-OSA trial results in Q1 2026 represent another important catalyst, potentially expanding lorundrostat's addressable market to include obstructive sleep apnea and hypertension, which could further enhance its commercial value.
At the time of this filing, MLYS was trading at $35.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $8.24 to $47.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.